Compare CMCT & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | DARE |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.9M |
| IPO Year | 1996 | 2014 |
| Metric | CMCT | DARE |
|---|---|---|
| Price | $2.67 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 26.2K | ★ 827.9K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,669,000.00 | $2,807,885.00 |
| Revenue This Year | N/A | $2,115.12 |
| Revenue Next Year | N/A | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.69 |
| 52 Week High | $14.41 | $3.78 |
| Indicator | CMCT | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 28.60 | 26.95 |
| Support Level | $2.16 | N/A |
| Resistance Level | $5.14 | $2.21 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 2.21 | 12.71 |
Creative Media & Community Trust Corp is a Maryland corporation and REIT. It mainly acquires, develops, owns, and operates both multifamily properties situated in vibrant communities throughout the United States and Class A and creative office real assets in markets with similar business and employment characteristics to multifamily investments. All of its communities are located in areas that include traditional downtowns and suburban main streets, which have high barriers to entry, high population density, positive population trends, and a propensity for growth. Currently, the company consists of three types of commercial real estate properties, namely office, hotel, and multifamily.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.